What Researchers Did
The researchers took tumor biopsy samples from patients with oropharyngeal cancer and measured how fast the tumor cells were dividing before and during radiotherapy.
What They Found
In patients with oropharyngeal cancer, this study found that the drop in tumor cell growth markers (labeling index and growth fraction) during radiotherapy was a more important sign of tumor response to radiation than their starting values. A fall to 0 or a sharp decrease in these values was a favourable sign and pointed to high tumor sensitivity to radiation, which allowed radiotherapy to continue on the radical program. A tumor was considered radioresistant if these values rose by the end of the interval in the middle of a split course. The authors reported that patients with resectable tumors should finish treatment with an operation. For unresectable tumors, treatment should be followed by combined radiotherapy with an increased dose of interstitial gamma-therapy. The abstract gives no sample size or p-values.
What This Means for Canadian Patients
The abstract does not address hyperbaric oxygen therapy. It describes how changes in tumor cell growth markers during radiotherapy were used to judge how a tumor was responding and to guide the next treatment steps in oropharyngeal cancer. It gives no information about HBOT.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The abstract does not report how many patients were studied, gives no statistical tests, and does not describe a comparison group, so the strength of these prognostic and treatment conclusions cannot be judged from it.